Form 10-Q · Quarterly report
Microchip Technology 10-Q, filed Nov 5, 2026
- Filed
- CIK
- 0000827054
- Accession no.
- 0000827054-26-000062
Summary
Microchip Technology said its fiscal 2026 business improved as customers worked through excess inventory, with net sales rising sequentially across every product line and geography in the quarter ended September 30, 2026, after a March 2025 restructuring and cost-reduction plan. The company flagged continued uncertainty over macroeconomic conditions, geopolitical tensions, and potential trade policies including tariffs.
Key points
- Microchip implemented a business recovery plan in March 2025 that included restructuring, resizing manufacturing operations, and reducing headcount.
- Net sales rose sequentially in each product line and each geography in the September 2026 quarter compared with the June 2026 quarter.
- After multiple quarters of revenue growth, Microchip reduced inventory and adjusted holdings to support growth while managing supply chain constraints.
- The company cited uncertainty from geopolitical tensions, recession risk, and potential trade policies including tariffs.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations Note Regarding Forward-looking Statements This report, including "Part I – Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Part II - Item 1A. Risk Factors" contains certain forward-looking statements that involve risks and uncertainties, including statements regarding our strategy, financial performance and revenue sources. We use words such as "anticipate," "believe," "can," "continue," "could," "expect," "future," "intend," "plan," and similar expressions to identify forward-looking statements. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.